Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G1T48 Alone and in Combination With Palbociclib in Advanced Breast Cancer
NCT03455270Phase 1Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- May 2018
- Primary completion
- Sep 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 1, open-label trial of rintodestrant in breast cancer (4 arms), sponsored by G1 Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicity, Recommended Phase 2 dose at 12 months and 1 more. Started May 2018; status: completed.
02
Drugs
rintodestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03455270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455270.